Topical difluprednate for the treatment of Harada’s disease

Topical difluprednate for the treatment of Harada’s disease

Spencer M Onishi, Masumi G Asahi, Calvin Chou, Ron P Gallemore Retina Macula Institute, Torrance, CA, USA Purpose: To describe the use of topical difluprednate for treatment of patients who presented with Harada’s disease.Methods: Retrospective case series of patients managed wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Onishi SM, Asahi MG, Chou C, Gallemore RP
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/2c615864caf9422e9d98fdefcea5d888
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2c615864caf9422e9d98fdefcea5d888
record_format dspace
spelling oai:doaj.org-article:2c615864caf9422e9d98fdefcea5d8882021-12-02T02:11:50ZTopical difluprednate for the treatment of Harada’s disease1177-5483https://doaj.org/article/2c615864caf9422e9d98fdefcea5d8882015-01-01T00:00:00Zhttp://www.dovepress.com/topical-difluprednate-for-the-treatment-ofnbspharadarsquos-disease-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Spencer M Onishi, Masumi G Asahi, Calvin Chou, Ron P Gallemore Retina Macula Institute, Torrance, CA, USA Purpose: To describe the use of topical difluprednate for treatment of patients who presented with Harada’s disease.Methods: Retrospective case series of patients managed with topical difluprednate alone at the onset of the diagnosis. The patients were followed with optical coherence tomography (OCT) and fluorescein angiography.Results: In our three cases, complete resolution of the exudative detachments with improvement in visual acuity was achieved in each case. Central macular thickness was reduced by a mean of 365±222 µm. Initial loading dose was one drop every hour while awake, followed by a variable tapering regimen. Leakage on fluorescein angiography and exudative detachments on OCT both responded to treatment with difluprednate. In two of the three cases, the patients recovered vision to 20/20, and the third case recovered to 20/25. Steroid-induced glaucoma was observed and managed with one to two glaucoma drops as needed.Conclusion: Difluprednate is effective for managing ocular manifestations of Harada’s disease. Further studies of this drug for the management of noninfectious posterior uveitis are warranted. Keywords: serous retinal detachment, noninfectious posterior uveitis, steroidOnishi SMAsahi MGChou CGallemore RPDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 157-167 (2015)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Onishi SM
Asahi MG
Chou C
Gallemore RP
Topical difluprednate for the treatment of Harada’s disease
description Spencer M Onishi, Masumi G Asahi, Calvin Chou, Ron P Gallemore Retina Macula Institute, Torrance, CA, USA Purpose: To describe the use of topical difluprednate for treatment of patients who presented with Harada’s disease.Methods: Retrospective case series of patients managed with topical difluprednate alone at the onset of the diagnosis. The patients were followed with optical coherence tomography (OCT) and fluorescein angiography.Results: In our three cases, complete resolution of the exudative detachments with improvement in visual acuity was achieved in each case. Central macular thickness was reduced by a mean of 365±222 µm. Initial loading dose was one drop every hour while awake, followed by a variable tapering regimen. Leakage on fluorescein angiography and exudative detachments on OCT both responded to treatment with difluprednate. In two of the three cases, the patients recovered vision to 20/20, and the third case recovered to 20/25. Steroid-induced glaucoma was observed and managed with one to two glaucoma drops as needed.Conclusion: Difluprednate is effective for managing ocular manifestations of Harada’s disease. Further studies of this drug for the management of noninfectious posterior uveitis are warranted. Keywords: serous retinal detachment, noninfectious posterior uveitis, steroid
format article
author Onishi SM
Asahi MG
Chou C
Gallemore RP
author_facet Onishi SM
Asahi MG
Chou C
Gallemore RP
author_sort Onishi SM
title Topical difluprednate for the treatment of Harada’s disease
title_short Topical difluprednate for the treatment of Harada’s disease
title_full Topical difluprednate for the treatment of Harada’s disease
title_fullStr Topical difluprednate for the treatment of Harada’s disease
title_full_unstemmed Topical difluprednate for the treatment of Harada’s disease
title_sort topical difluprednate for the treatment of harada’s disease
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/2c615864caf9422e9d98fdefcea5d888
work_keys_str_mv AT onishism topicaldifluprednateforthetreatmentofnbspharadarsquosdisease
AT asahimg topicaldifluprednateforthetreatmentofnbspharadarsquosdisease
AT chouc topicaldifluprednateforthetreatmentofnbspharadarsquosdisease
AT gallemorerp topicaldifluprednateforthetreatmentofnbspharadarsquosdisease
_version_ 1718402581629239296

Ejemplares similares